Wells Fargo & Company Intellia Therapeutics, Inc. Transaction History

Wells Fargo & Company

$434 Billion
Q3 2024

A detailed history of Wells Fargo & Company transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 200,820 shares of NTLA stock, worth $2.42 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

200,820

Previous 201,657 0.42%

Holding current value

$2.42 Million

Previous $4.51 Million 8.58%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$19.72 - $27.36 $16,505 - $22,900	-837 Reduced 0.42%	200,820 $4.13 Million
Q2 2024 Aug 13, 2024	SELL	$20.02 - $27.22 $282,302 - $383,829	-14,101 Reduced 6.54%	201,657 $4.51 Million
Q1 2024 May 10, 2024	BUY	$23.82 - $32.8 $313,566 - $431,779	13,164 Added 6.5%	215,758 $5.94 Million
Q4 2023 Feb 09, 2024	SELL	$23.16 - $32.34 $564,525 - $788,287	-24,375 Reduced 10.74%	202,594 $6.18 Million
Q3 2023 Nov 13, 2023	BUY	$31.62 - $45.78 $1.25 Million - $1.81 Million	39,566 Added 21.11%	226,969 $7.18 Million
Q2 2023 Aug 15, 2023	BUY	$34.58 - $46.03 $830,023 - $1.1 Million	24,003 Added 14.69%	187,403 $7.64 Million
Q1 2023 May 12, 2023	BUY	$33.3 - $44.82 $3.11 Million - $4.18 Million	93,314 Added 133.14%	163,400 $6.09 Million
Q4 2022 Feb 13, 2023	SELL	$33.21 - $62.69 $462,880 - $873,773	-13,938 Reduced 16.59%	70,086 $2.45 Million
Q3 2022 Nov 14, 2022	BUY	$53.92 - $71.7 $497,358 - $661,360	9,224 Added 12.33%	84,024 $4.7 Million
Q2 2022 Aug 12, 2022	SELL	$38.49 - $76.21 $936,923 - $1.86 Million	-24,342 Reduced 24.55%	74,800 $3.87 Million
Q1 2022 May 16, 2022	SELL	$58.27 - $118.99 $1.75 Million - $3.57 Million	-30,021 Reduced 23.24%	99,142 $7.21 Million
Q4 2021 Feb 14, 2022	BUY	$100.76 - $138.36 $70,532 - $96,852	700 Added 0.54%	129,163 $15.3 Million
Q3 2021 Nov 15, 2021	BUY	$132.37 - $176.78 $1.84 Million - $2.46 Million	13,899 Added 12.13%	128,463 $17.2 Million
Q2 2021 Aug 16, 2021	SELL	$60.88 - $161.91 $691,048 - $1.84 Million	-11,351 Reduced 9.01%	114,564 $18.6 Million
Q1 2021 May 13, 2021	SELL	$46.59 - $83.68 $1.34 Million - $2.41 Million	-28,846 Reduced 18.64%	125,915 $10.1 Million
Q4 2020 Feb 09, 2021	BUY	$18.83 - $63.53 $1.66 Million - $5.6 Million	88,173 Added 132.42%	154,761 $8.42 Million
Q3 2020 Nov 05, 2020	SELL	$17.47 - $24.93 $764,958 - $1.09 Million	-43,787 Reduced 39.67%	66,588 $1.32 Million
Q2 2020 Aug 13, 2020	BUY	$11.14 - $22.87 $330,278 - $678,049	29,648 Added 36.73%	110,375 $2.32 Million
Q1 2020 May 14, 2020	BUY	$9.44 - $15.58 $762,062 - $1.26 Million	80,727 New	80,727 $988,000

Others Institutions Holding NTLA

# of Institutions

314

Shares Held

91.5M

Call Options Held

442K

Put Options Held

880K

View Full List

About Intellia Therapeutics, Inc.

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $916M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

More about NTLA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Account

Wells Fargo & Company Intellia Therapeutics, Inc. Transaction History